AstraZeneca Pharma India Limited (ASTRAZEN) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of AstraZeneca Pharma India Limited ₹1,409, price ₹6,505, upside -78.4%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch AstraZeneca Pharma India Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹2,426 – ₹10,474 · fair‑value band ₹693.97 – ₹1,969 · the ₹6,505 price screens above the ₹1,409 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow AstraZeneca Pharma India in your weekly email
Every Wednesday you see whether AstraZeneca Pharma India is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally.
Show more
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Stock analysis
AstraZeneca Pharma India Limited (ASTRAZEN) currently trades at ₹6,505, while our model-based Fair Value estimate is ₹1,409, implying the stock looks roughly 361.9% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹1,848 per share, and 0 of the 25 models we run sit above the ₹6,505 price.
Bear case: the Asset-Based group reads lowest at ₹233.91, and 25 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹693.97 (bear) to ₹1,969 (bull), the price of ₹6,505 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
AstraZeneca Pharma India Limited reported revenue of ₹22.8B in FY2026 versus ₹8.1B in FY2022, a compound +29.6%/yr. Reported net income was ₹1.9B in FY2026, compounding +32.1%/yr from FY2022.
Key figures
Market cap ₹211B (≈ $2.2B) · P/E ratio 87.1 · P/S ratio 7.18 · EPS (TTM) ₹74.68 · Dividend yield 0.6% · Net margin 8.2% · Return on equity 22.8% · Return on assets (EBIT) 13.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −78%, ASTRAZEN screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹233.91 to ₹3,054). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹693.97Fair Value ₹1,409Bull ₹1,969
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹19.08 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Start year 2021 (pandemic). Over 10 years: +15.0% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+20.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+20.1%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.21.0% vs 30.9%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 10%
2026 sits 62% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare AstraZeneca Pharma India Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 619 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−78.3% · Bottom 25%
Profitability
Return on equity (TTM)22.8% · Top 25%
Return on assets8.3% · Top 25%
Net margin (TTM)8.2% · Above median
Operating margin (TTM)9.6% · Below median
Growth and dividend
Revenue growth20.4% · Top 25%
Dividend yield (TTM)0.6% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)87.1× · Priciest 25%
P/B24.18× · Priciest 25%
P/S (TTM)9.27× · Priciest 25%
P/FCF68.6× · Priciest 25%
EV/EBITDA78.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 18
PAST (return on equity)91· sector 26
HEALTH (low debt)0· sector 96
DIVIDEND (yield)11· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AstraZeneca Pharma India Limited Fair Value". https://www.fairvalue-calculator.com/stock/ASTRAZEN
Frequently asked questions
Is AstraZeneca Pharma India Limited (ASTRAZEN) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹1,409 versus a price of ₹6,505, about −78% upside (overvalued).
What is the fair value of ASTRAZEN?
Our model-based fair value for AstraZeneca Pharma India Limited is ₹1,409 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹6,505.
What is the quality score of ASTRAZEN?
AstraZeneca Pharma India Limited has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AstraZeneca Pharma India Limited (ASTRAZEN)?
Our model-based price target is the fair value of ₹1,409 (as of Sep 27, 2026) from 25 valuation models. Cautious scenario ₹693.97, optimistic scenario ₹1,969. It is a calculation from audited fundamentals, not an analyst target.
What is the AstraZeneca Pharma India Limited stock forecast for 2026?
Our models put fair value at ₹1,409, about −78% upside versus a price of ₹6,505 (overvalued). Cautious scenario ₹693.97, optimistic scenario ₹1,969. The calculation is refreshed regularly with new filings.
What is the revenue of AstraZeneca Pharma India Limited (ASTRAZEN)?
AstraZeneca Pharma India Limited reported trailing-twelve-month revenue of about ₹22.8B (latest available figure, as of Sep 27, 2026).
Does AstraZeneca Pharma India Limited pay a dividend?
AstraZeneca Pharma India Limited currently shows a dividend yield of about 0.55% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of AstraZeneca Pharma India Limited (ASTRAZEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AstraZeneca Pharma India Limited it is ₹1,409 per share (as of Sep 27, 2026), against a price of ₹6,505. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is AstraZeneca Pharma India Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, ASTRAZEN trades above its calculated fair value: price ₹6,505, fair value ₹1,409, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASTRAZEN?
No. The price is what the market pays today (₹6,505); the fair value is what the company's own numbers justify (₹1,409). For AstraZeneca Pharma India Limited the two are ₹5,096 per share apart. That gap is exactly why we show both numbers side by side.
How much is AstraZeneca Pharma India Limited worth?
The market values AstraZeneca Pharma India Limited at about ₹211B (market capitalisation, as of Sep 27, 2026). Per share that is ₹6,505; our models calculate a fair value of ₹1,409 per share.
What do the bullish and bearish scenarios say about ASTRAZEN?
Our models span a range for AstraZeneca Pharma India Limited: cautious scenario ₹693.97, base ₹1,409, optimistic ₹1,969 per share (as of Sep 27, 2026, price ₹6,505). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ASTRAZEN?
AstraZeneca Pharma India Limited trades at a price-to-earnings ratio of 87.1 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,409 is built from several models across several years. Other multiples: P/B 24.2, P/S 9.3, EV/EBITDA 78.8.
How solid is the balance sheet of AstraZeneca Pharma India Limited (ASTRAZEN)?
Balance-sheet figures for AstraZeneca Pharma India Limited (as of Sep 27, 2026): return on equity 22.8%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is ASTRAZEN from its 52-week high?
AstraZeneca Pharma India Limited trades at ₹6,505, about 34% below its 52-week high of ₹9,828 and at the low of ₹6,505 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,409 is for.
Which stocks are comparable to AstraZeneca Pharma India Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AstraZeneca Pharma India Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹6,505, calculated fair value ₹1,409 (−78%), Quality Score 58/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASTRAZEN calculated?
We run AstraZeneca Pharma India Limited through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,409, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. AstraZeneca Pharma India Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AstraZeneca Pharma India Limited (ASTRAZEN)?
The closing price on Sep 25, 2026 was ₹6,505. Our model-based fair value is ₹1,409, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AstraZeneca Pharma India Limited right now?
The price sits above even our optimistic bull case (₹1,969). The favourable scenario is already priced in. The model range is unusually wide (₹693.97 to ₹1,969). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of AstraZeneca Pharma India Limited
How large is the market capitalisation of AstraZeneca Pharma India Limited (ASTRAZEN)?
The market capitalisation of AstraZeneca Pharma India Limited is ₹211B (≈ $2.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AstraZeneca Pharma India Limited (ASTRAZEN)?
The price-to-sales ratio of AstraZeneca Pharma India Limited is 7.18 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AstraZeneca Pharma India Limited (ASTRAZEN)?
Earnings per share at AstraZeneca Pharma India Limited are ₹74.68 (price ÷ EPS = P/E 87.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AstraZeneca Pharma India Limited (ASTRAZEN)?
The dividend yield of AstraZeneca Pharma India Limited is 0.6% (payout 48.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AstraZeneca Pharma India Limited (ASTRAZEN)?
The net margin of AstraZeneca Pharma India Limited is 8.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AstraZeneca Pharma India Limited (ASTRAZEN)?
The return on equity (ROE) of AstraZeneca Pharma India Limited is 22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AstraZeneca Pharma India Limited (ASTRAZEN)?
On an EBIT basis the return on assets of AstraZeneca Pharma India Limited is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AstraZeneca Pharma India Limited (ASTRAZEN)?
The operating margin of AstraZeneca Pharma India Limited is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AstraZeneca Pharma India Limited (ASTRAZEN)?
Revenue at AstraZeneca Pharma India Limited is growing +20.4% versus a year earlier (3y avg +31.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AstraZeneca Pharma India Limited (ASTRAZEN)?
Earnings per share at AstraZeneca Pharma India Limited are growing −23.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does AstraZeneca Pharma India Limited (ASTRAZEN) generate?
The free cash flow of AstraZeneca Pharma India Limited is ₹32.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does AstraZeneca Pharma India Limited (ASTRAZEN) hold?
AstraZeneca Pharma India Limited holds more cash than debt, ₹3.4B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch AstraZeneca Pharma India Limited in the live analysis
One click puts AstraZeneca Pharma India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
